effects, and tended to have more comorbidities at MTX initiation than those who persisted on therapy.

Acknowledgement: This study was sponsored by Corrona, LLC. Corrona is supported through contracted subscriptions with multiple pharmaceutical companies. The abstract was a collaborative effort between Corrona and AbbVie with financial support provided by AbbVie.

Clinical Disease Characteristics and Outcomes by Pattern of MTX Use				
	Discontinued/Restarted (N=34)	Discontinued (N=174)	Persisted (N=577)	P-value
CDAI change over 2-year follow-up				
Change from baseline in CDAI, mean $\pm$ SD	3.1 $\pm$ 15.6	7.4 $\pm$ 14.9	10.4 $\pm$ 13.6	<0.01
Achieved LDA, ^a n (%)	10 (29.4)	58 (33.3)	213 (36.9)	0.50
Achieved MCID, ^b n (%)	14 (41.2)	86 (49.4)	332 (57.5)	0.04
Outcomes at end of MTX use or 2-year follow-up				
CDAI, mean $\pm$ SD	15.6 $\pm$ 14.4	10.1 $\pm$ 9.3	8.8 $\pm$ 9.5	0.001
mHAQ, mean $\pm$ SD	0.5 $\pm$ 0.7	0.4 $\pm$ 0.5	0.2 $\pm$ 0.4	<0.001
Physician Global Assessment, mean $\pm$ SD	22.0 $\pm$ 20.6	18.1 $\pm$ 16.4	14.4 $\pm$ 15.4	<0.01
Patient Global Assessment, mean $\pm$ SD	39.4 $\pm$ 32.5	31.3 $\pm$ 26.7	25.2 $\pm$ 25.0	<0.01
Pain, mean $\pm$ SD	39.1 $\pm$ 32.5	33.9 $\pm$ 27.3	27.2 $\pm$ 26.2	<0.01
Fatigue, mean $\pm$ SD	44.0 $\pm$ 35.0	32.5 $\pm$ 29.5	27.2 $\pm$ 26.8	0.06
Morning stiffness, n (%)	23 (67.7)	127 (74.3)	359 (63.5)	0.03
Morning stiffness duration (h), mean $\pm$ SD	1.5 $\pm$ 4.0	1.3 $\pm$ 3.2	0.7 $\pm$ 1.9	<0.001

CDAI, Clinical Disease Activity Index; CPP, cyclic citrullinated peptide; LDA, low disease activity; MCID, minimum clinically important difference; mHAQ, modified Health Assessment Questionnaire; SD, standard deviation.

^aAchievement of LDA (CDAI $\leq$ 10) in those patients who initiated therapy in moderate (10<CDAI $\leq$ 22) or high disease activity (CDAI $\geq$ 22).

^bCDAI change $\geq$ 1 for those in LDA (CDAI $\leq$ 10) at baseline, CDAI change $\geq$ 6 for those in moderate disease activity (10<CDAI $\leq$ 22) at baseline, and CDAI change $\geq$ 12 for those in high disease activity (CDAI $\geq$ 22) at baseline.

Disclosure of Interests: Leslie Harrold Shareholder of: Corrona, Grant/ research support from: Pfizer, Consultant for: AbbVie, BMS, and Genentech, Employee of: Corrona, Heather J. Litman: None declared, Jacqueline O'Brien Employee of: Corrona, Hua Feng Employee of: Corrona, Casey Schlacher Shareholder of: AbbVie, Employee of: AbbVie, Namita Tundia Shareholder of: AbbVie, Employee of: AbbVie
DOI: 10.1136/annrheumdis-2019-eular.1009

FRI0153

OPHTHALMOLOGICAL ADVERSE EVENTS UNDER JAK INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: CASE ANALYSIS OF THE EUROPEAN PHARMACOVIGILANCE DATABASE

Sophie Hecquet¹, Marie Blanche Rabier¹, Marion Lepelletier², Frank Verhoeven¹, Anne Sophie Gauthier¹, Clément Prati¹, Bernard Delbos¹, Daniel Wendling¹.
¹Centre hospitalier régional universitaire de Besançon, Besançon, France; ²Centre Hospitalier Universitaire de Grenoble, La Tronche, France

Background: Ophthalmological manifestations in rheumatoid arthritis (RA) include dry syndrome, scleritis, episcleritis, uveitis and peripheral ulcerative keratitis (PUK). Recently, a new class of synthetic molecules has been developed, called JAK inhibitors (JAKinhib). We observed one case of PUK occurring two months after the introduction of baricitinib treatment with corneal perforation with secondary improvement after discontinuation of JAKinhib.

Objectives: The aim of this study is to describe and characterize the ophthalmological side effects of JAK inhibitors (JAK inhib) in patients with rheumatoid arthritis (RA) from European pharmacovigilance (PV) data.

Methods: The ophthalmological manifestations that appeared under JAK inhib were extracted from the European PV database (May 2018), EUDRAVIGILANCE following a request addressed to the National Drug Safety Agency carried out according to the following MedDRA classification "SOC eye disorders and BARICITINIB" and "SOC eye disorders and TOFACITINIB".

Results: A total of 41 patients with ophthalmic adverse events (AEs) on JAK inhib were reported. Among patients, 12 were treated with BARICITINIB and 29 with TOFACITINIB. Of these AEs, 51% were reported by the medical profession, 39% by patients and 10% by paramedical teams. The database analysis revealed 4 scleritis, 3 uveitis, 1 PUK and 1 corneal ulceration. The average time to onset of AEs was 13.2 months. The infectious causes had been eliminated.

Ocular adverse events under JAK inhibitors

	BARICITINIB n=12	TOFACITINIB n=29	Mean Delay (in days)
Ophthalmological events	AEs	AEs	
Scleritis**, n (%)	2 (17)	2 (7)	344
Corneal ulceration**, n (%)	0	1 (3)	90
PUK**, n (%)	1 (8)	0	57
Uveitis**, n (%)	0	3 (10)	838
Blurry vision*, n (%)	3 (25)	8 (28)	9
Red eyes*, n (%)	3 (25)	1 (3)	33
Dry eyes*, n (%)	2 (17)	3 (10)	NA
Photophobia*, n (%)	0	1 (3)	NA
Decreased visual acuity*, n (%)	1 (8)	1 (3)	124
Retinal detachment**, n (%)	0	1 (3)	480
Retinal haemorrhage**, n (%)	0	2 (7)	541
Cataract**, n (%)	2 (17)	5 (17)	413
Glaucoma**, n (%)	0	4 (14)	489
Age related macular degeneration**, n (%)	0	1 (3)	NA

*Adverse event reported by the patient **Adverse event reported by the medical profession
PUK: Peripheral Ulcerative Keratitis NA: Not Available

Conclusion: Ophthalmological manifestations under JAKinhib seem to be rare but not exceptional, the rheumatologist must be aware of them in order to discuss the imputability of the treatment. A discontinuation of it seems justified pending an ophthalmological opinion.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.3811

FRI0154

SAFETY AND EFFICACY OF FILGOTINIB IN PATIENTS AGED 65 YEARS AND OLDER: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR)

Kenneth Kalunian¹, Jacques-Eric Gottenberg², Mark C. Genovese³, Neelufar Mozaffarian⁴, Beatrix Bartok⁴, Franziska Matzkies⁴, Jie Gao⁴, Ying Guo⁴, Tsutomu Takeuchi⁵, Kurt de Vlam⁶, David Walker⁷.
¹University of California, San Diego, La Jolla, United States of America; ²Dept of Rheumatology, Strasbourg University Hospital, Strasbourg, France; ³Stanford University Medical Center, Palo Alto, United States of America; ⁴Gilead Sciences, Inc., Foster City, United States of America; ⁵Keio University School of Medicine, Tokyo, Japan; ⁶Universitair Ziekenhuis Leuven, Leuven, Belgium; ⁷Northumbria Healthcare, Newcastle upon Tyne, United Kingdom

Background: Filgotinib (FIL), an oral selective Janus kinase 1 (JAK1) inhibitor, demonstrated efficacy and safety vs placebo (PBO) in bDMARD-IR patients with active RA in a global phase 3 study (FINCH2, ClinicalTrials.gov NCT02873936).¹

Objectives: We performed a prespecified subgroup analysis of the safety and efficacy of FIL in patients aged $\geq$ 65 years vs <65 years in FINCH2 to understand FIL effects in older patients.

Methods: 449 patients were randomized 1:1:1 to FIL 200 mg, FIL 100 mg, or PBO on a background of csDMARDs for 24 weeks. The primary efficacy endpoint was ACR20 response at week 12.

Results: Of 448 patients who received $\geq$ 1 dose of study drugs, 113 (25.2%) were $\geq$ 65 years of age; baseline disease characteristics were similar for both age groups. Safety and efficacy parameters by age group are in Tables 1 and 2. The most common treatment-emergent adverse events (TEAEs, by System Organ Class) category was infections and infestations; nasopharyngitis, upper respiratory tract infections, and bronchitis were the most common infections and infestations in the FIL arms in both age groups. There were no cases of opportunistic infection, active tuberculosis, malignancy, gastrointestinal perforation, or death. Efficacy outcomes were similar for both groups.

Conclusion: Overall, older age was not associated with higher incidence of safety events (serious infections, herpes zoster, MACE occurred in the group <65 yrs) and efficacy was similar in older and younger bDMARD-IR patients with active RA.

REFERENCE:

[1] MC Genovese, et al. ACR, 2018. Abstract L06.